Preliminary Safety and Efficacy Results of EDI001: An Investigator Initiated Trial on CRISPR/Cas9-Modified Autologous CD34+ Hematopoietic Stem and Progenitor Cells for Patients with Transfusion Dependent β-Thalassemia

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2022-11, Vol.140 (Supplement 1), p.10652-10653
Hauptverfasser:	Shi, Jun, Fang, Riguo, Gao, Zhen, Shi, Zhongyu, Kuang, Zhexiang, Zhang, Yongjian, Zhang, Lele, Yang, Huihui, Zhang, Yingchi, Zou, Dehui, Fang, Liwei, Sun, Jiali, Li, Qiang, Zou, Yao, Pan, Hong, Zhao, Jingyu, Li, Liyun, Yu, Xiao, Xu, Jing, Xu, Chun, Liu, Yanjie, Wang, Weiwei, Shi, Jia, Liu, Jie, Wang, Jia, Shi, Nian, Yang, Lei, Wang, Weiqiang, Li, Suyi, Shi, Moye, Zhang, Xiaoshuang, Yuan, Pengfei, Wei, Wensheng, Wei, Dong, Cheng, Tao
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!